Three Rivers Pharmaceuticals® welcomes you to learn more about the company and its products. Established in 2000, Three Rivers Pharmaceuticals devotes its efforts and resources to developing, manufacturing, and marketing pharmaceutical therapies which are indicated for diseases/medical conditions requiring specialized treatment. Currently, Three Rivers Pharmaceuticals markets prescription drugs in both the U.S. and internationally, in the therapeutic categories of antiviral and antifungal agents.

The company has continued to expand its product line into the branded market with the acquisition of AMPHOTEC®/AMPHOCIL® in May of 2005. This product is currently being marketed in over 40 countries worldwide.

In addition, Three Rivers Pharmaceuticals has broadened its presence in the hepatitis C market with the December 2005 launch of Ribasphere® Tablets and RibaPak™. With the development of these therapies, Three Rivers Pharmaceuticals has helped many patients around the world improve the quality of their treatment.